Climb Bio IncCLYM
Price$11.07

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$57.6MTTM through 30 Jun 2026
Free Cash Flow -$53.1MTTM through 30 Jun 2026

Margins

Current

Returns

-37.3%ROE
-35.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio23.74x
Net Debt-$101.1Mnet cash position
Cash & Equivalents$44.1M

Quality Metrics

Altman Z-Score70.79
Piotroski F-Score3 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$0.82TTM
'20'21'22'23'24'25
FY2025: $-0.88

Dividend

No dividend

Capital Allocation

R&D Spend$41.9M

Segment Performance

SegmentRevenueYoYOutlook
Biotechnology$0
View details

Climb Bio operates as a single segment focused on developing therapeutics for immune-mediated diseases. Key clinical readouts for budoprutug and CLYM116 are anticipated throughout 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.